News 2024 - Appili Therapeutics

NEWS

Highlights

NEWS

NEWS 2024

November 19, 2024

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

November 14, 2024

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

November 6, 2024

Appili Therapeutics Announces Results of Special Meeting of Shareholders

October 31, 2024

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

October 17, 2024

Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024

October 10, 2024

Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders

September 17, 2024

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

August 21, 2024

Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt

August 13, 2024

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025

July 18, 2024

Appili Therapeutics Announces Second Amendment to Arrangement Agreement

July 2, 2024

Appili Therapeutics Announces Amendment to Arrangement Agreement and Increase to Bridge Loan

June 25, 2024

Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results

April 26, 2024

Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.

April 2, 2024

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

March 12, 2024

Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

February 13, 2024

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024